Self-Shielding Gyroscopic Radiosurgery Patient Analysis

This document is a research article that presents a prospective analysis of the first 100 patients treated with self-shielding gyroscopic radiosurgery (GRS) for intracranial tumors. The study outlines the background of stereotactic radiosurgery (SRS) as a treatment option for various brain tumors and discusses the introduction of GRS, which allows for treatment without the need for shielded radiation vaults. The materials and methods section details the patient enrollment criteria, treatment planning, and follow-up assessments conducted from December 2021 to March 2023. Results indicate that the most commonly treated tumors included brain metastases, vestibular schwannomas, and meningiomas, with a median prescription dose of 20 Gy for malignant tumors and 13 Gy for benign tumors. The study reports on dosimetric performance indices, treatment times, and patient satisfaction, concluding that initial experiences with GRS are favorable. Further clinical and dosimetric evaluations are suggested to validate these findings.